The current status of oncolytic viral therapy for head and neck cancer

被引：0

作者：

Old Matthew O

WiseDraper Trisha ^{[1
,2
,3
,4
]}

Wright Chadwick L ^{[5
,6
,7
,8
,4
]}

Kaur Balveen ^{[9
,10
,11
,4
]}

Teknos Theodoros ^{[12
,13
,14
,4
]}

机构：

[1] Division of Hematology-Oncology

[2] Department of Internal Medicine

[3] University of Cincinnati

[4] USA

[5] Wright Center of Innovation in Biomedical Imaging

[6] Division of Nuclear Medicine and Molecular Imaging

[7] Department of Radiology

[8] The Ohio State University Wexner Medical Center

[9] Department of Neurological Surgery

[10] Dardinger Laboratory for Neuro-Oncology and Neurosciences

[11] The Ohio State University Comprehensive Cancer Center

[12] Department of Otolaryngology - Head and Neck Surgery

[13] The James Cancer Hospital and Solove Research Institute

[14] Wexner Medical Center at The Ohio State

来源：

世界耳鼻咽喉头颈外科杂志（英文）. | 2016年 / 2卷 / 02期

关键词：

Head and neck squamous cell carcinoma; Oncolytic viruses; Clinical trials; Novel therapeutics;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Objective: Cancer affects the head and neck region frequently and leads to significant morbidity and mortality. Oncolytic viral therapy has the potential to make a big impact in cancers that affect the head and neck. We intend to review the current state of oncolytic viruses in the treatment of cancers that affect the head and neck region. Method: Data sources are from National clinical trials database, literature, and current research. Results: There are many past and active trials for oncolytic viruses that show promise for treating cancers of the head and neck. The first oncolytic virus was approved by the FDA October 2015 (T-VEC, Amgen) for the treatment of melanoma. Active translational research continues for this and many other oncolytic viruses. Conclusion: The evolving field of oncolytic viruses is impacting the treatment of head and neck cancer and further trials and agents are moving forward in the coming years.

引用

共 50 条

[1] The current status of oncolytic viral therapy for head and neck cancer
Old Matthew O.
Wise-Draper Trisha
Wright Chadwick L.
Kaur Balveen
Teknos Theodoros
[J]. 世界耳鼻咽喉头颈外科杂志英文版, 2016, (02) : 84 - 89
[2] Current status of systemic therapy in head and neck cancer
Mittal, Abhenil
Sharma, Atul
[J]. JOURNAL OF CHEMOTHERAPY, 2022, 34 (01) : 9 - 24
[3] Current status of head and neck cancer therapy in the elderly
Sesterhenn, A. M.
[J]. LARYNGO-RHINO-OTOLOGIE, 2007, 86 (02) : 95 - 100
[4] Current status of gene therapy for lung cancer and head and neck cancer
Moon, C
Oh, Y
Roth, JA
[J]. CLINICAL CANCER RESEARCH, 2003, 9 (14) : 5055 - 5067
[5] Viral gene therapy for head and neck cancer
Hughes, J. P.
Alusi, G.
Wang, Y.
[J]. JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2015, 129 (04): : 314 - 320
[6] Current status of biomarkers in head and neck cancer
Chang, Steven S.
Califano, Joseph
[J]. JOURNAL OF SURGICAL ONCOLOGY, 2008, 97 (08) : 640 - 643
[7] Current status of IMRT in head and neck cancer
Gomez-Millan, Jaime
Romero Fernandez, Jesus
Medina Carmona, Jose Antonio
[J]. REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2013, 18 (06) : 371 - 375
[8] Oncolytic virotherapy for head and neck cancer: current research and future developments
Malhotra, Akshiv
Sendilnathan, Arun
Old, Matthew O.
Wise-Draper, Trisha M.
[J]. ONCOLYTIC VIROTHERAPY, 2015, 4 : 83 - 93
[9] Oncolytic virotherapy in head and neck cancer
Runge, Annette
Petersson, Monika
Riechelmann, Herbert
[J]. LARYNGO-RHINO-OTOLOGIE, 2022, 101 (10) : 787 - 796
[10] Current status of experimental therapeutics for head and neck cancer
Lee, Juna
Moon, Chulso
[J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2011, 236 (04) : 375 - 389

← 1 2 3 4 5 →